Enduring Material

11th Annual Seminar on Hepatitis and Chronic Liver Disease
View Activity Info
Enter Basic User Info
Create Account
Select Registrant Type
Submit Payment
View Content
Take Post Test
Done
View Activity Info
Continue to Enduring Material
 
 
Colorado Medical Society

7351 Lowry Blvd, Suite 110
Denver, CO 80230-6902
General Information
Monday, July 13, 2026 - Thursday, December 31, 2027
390 minutes
SC Liver Research Consortium
Virtual Conference Room
11th Annual Seminar on Hepatitis and Chronic Liver Disease (Enduring Material)
Colorado Medical Society
Save this Date to your Personal Calendar
Presentations and Speakers
Presentations:
11th Annual Seminar on Hepatitis and Chronic Liver Disease
  • Howard Horwitz, MPH
2. Viral Hepatitis Overview
  • Julio Gutierrez, MD
3. Viral Hepatitis: B & C
  • Nancy Reau, MD - Rush University
4. The Hepatitis Delta Virus and Interaction with HBV
  • Paul J. Pockros, MD, Hepatology - Scripps Clinic and Scripps Research Institute
5. Cholestatic Liver Disease: PBC, PSC, and Pruritus
  • Paul J. Pockros, MD, Hepatology - Scripps Clinic and Scripps Research Institute
6. Metabolic Associated Fatty Liver Disease/Metabolic Associated Steatohepatitis
  • Paul J. Pockros, MD, Hepatology - Scripps Clinic and Scripps Research Institute
7. Alcohol-Associated Liver Disease (ALD)
  • Craig McClain, MD - University of Louisville
8. Hepatocellular Carcinoma (HCC) in 2026
  • Amit Singal, MD - UT Southwestern Medical Center
9. End-Stage Liver Disease: Cirrhosis, Complications, and Transplant
  • Neil Shah, MD
10. The Effective Management of Ascites and Hepatorenal Syndrome (HRS)
  • Adrian DiBisceglie, MD, Hepatology
11. EASL Recap
  • Paul J. Pockros, MD, Hepatology - Scripps Clinic and Scripps Research Institute
Available Credits/Points
  • The Colorado Medical Society designates this enduring material for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The Colorado Medical Society designates this enduring material for a maximum of 6.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statements
CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Speakers:
Howard Horwitz, MPH, FACHE has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Adrian DiBisceglie, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Astra Zeneca - Review Panel Member - Relationship Has Not Ended
  • Boston Pharmaceuticals - Advisory Committee Member - Relationship Ended
  • Nammi Pharmaceuticals - Consulting - Relationship Ended
  • Akero - Contracted Research - Relationship Has Not Ended
Julio Gutierrez, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Madrigal - Speakers Bureau - Relationship Has Not Ended
  • Abbvie - Speakers Bureau - Relationship Has Not Ended
  • Gilead - Speakers Bureau - Relationship Has Not Ended
Craig McClain, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • NovoNordisk - Speakers Bureau - Relationship Has Not Ended
  • National Institutes of Health - Contracted Research - Relationship Has Not Ended
  • Veterans Administration - Employment - Relationship Has Not Ended
Paul J. Pockros, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Gilead - Speakers Bureau - Relationship Has Not Ended
  • Gilead - Advisory Committee Member - Relationship Has Not Ended
  • Ipsen - Speakers Bureau - Relationship Has Not Ended
  • Ipsen - Advisory Committee Member - Relationship Has Not Ended
  • Madrigal - Advisory Committee Member - Relationship Has Not Ended
  • Madrigal - Speakers Bureau - Relationship Has Not Ended
  • Novo - Speakers Bureau - Relationship Has Not Ended
  • Mirum - Consulting - Relationship Has Not Ended
  • Intercept - Consulting - Relationship Ended
  • Orphalan - Advisory Committee Member - Relationship Has Not Ended
  • Boston Pharmaceuticals - Review Panel Member - Relationship Ended
  • f5 Therapeutics - Board Member - Relationship Has Not Ended
Nancy Reau, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • VIR - Consulting - Relationship Has Not Ended
  • VIR - Contracted Research - Relationship Has Not Ended
  • Bluejay - Consulting - Relationship Ended
  • Bluejay - Contracted Research - Relationship Has Not Ended
  • Gilead - Contracted Research - Relationship Ended
  • Gilead - Consulting - Relationship Has Not Ended
  • Ipsen - Consulting - Relationship Has Not Ended
  • salix - Consulting - Relationship Ended
  • Salix - Contracted Research - Relationship Has Not Ended
Neil Shah, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Ipsen - Consulting - Relationship Has Not Ended
  • GSK - Teaching - Relationship Has Not Ended
Amit Singal, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • AstraZeneca - Consulting - Relationship Has Not Ended
  • Genentech - Consulting - Relationship Has Not Ended
  • Eisai - Consulting - Relationship Has Not Ended
  • Exelixis - Consulting - Relationship Ended
  • Merck - Consulting - Relationship Ended
  • Bayer - Consulting - Relationship Ended
  • Elevar - Consulting - Relationship Has Not Ended
  • Boston Scientific - Consulting - Relationship Has Not Ended
  • Sirtex - Consulting - Relationship Ended
  • Exact Sciences - Consulting - Relationship Has Not Ended
  • FujiFilm Medical Sciences - Consulting - Relationship Has Not Ended
  • Helio Genomics - Consulting - Relationship Has Not Ended
  • DELFI - Consulting - Relationship Has Not Ended
  • Curve Biosciences - Consulting - Relationship Has Not Ended
  • Mursla - Consulting - Relationship Has Not Ended
  • Universal Dx - Consulting - Relationship Has Not Ended
  • Verve - Consulting - Relationship Has Not Ended

Planners and other Administrative Support:
Howard Horwitz, MPH, FACHE and Anne Larson, MD, FAASLD, FACP, AGAF have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Paul J. Pockros, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Gilead - Speakers Bureau - Relationship Has Not Ended
  • Gilead - Advisory Committee Member - Relationship Has Not Ended
  • Ipsen - Speakers Bureau - Relationship Has Not Ended
  • Ipsen - Advisory Committee Member - Relationship Has Not Ended
  • Madrigal - Advisory Committee Member - Relationship Has Not Ended
  • Madrigal - Speakers Bureau - Relationship Has Not Ended
  • Novo - Speakers Bureau - Relationship Has Not Ended
  • Mirum - Consulting - Relationship Has Not Ended
  • Intercept - Consulting - Relationship Ended
  • Orphalan - Advisory Committee Member - Relationship Has Not Ended
  • Boston Pharmaceuticals - Review Panel Member - Relationship Ended
  • f5 Therapeutics - Board Member - Relationship Has Not Ended
Nancy Reau, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • VIR - Advisory Committee Member - Relationship Has Not Ended
  • VIR - Contracted Research - Relationship Has Not Ended
  • Bluejay - Advisory Committee Member - Relationship Has Not Ended
  • Bluejay - Contracted Research - Relationship Has Not Ended
  • Salix - Advisory Committee Member - Relationship Ended
  • Ipsen - Advisory Committee Member - Relationship Ended
  • Mirum - Advisory Committee Member - Relationship Has Not Ended
  • Gilead - Advisory Committee Member - Relationship Has Not Ended
Craig McClain, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • VAMC - Employment - Relationship Has Not Ended
  • National Institutes of Health - Contracted Research - Relationship Has Not Ended
Adrian DiBisceglie, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • Astra Zeneca - Review Panel Member - Relationship Has Not Ended
  • Boston Pharmaceuticals - Advisory Committee Member - Relationship Ended
  • Nammi Pharmaceuticals - Consulting - Relationship Ended
  • Akero - Contracted Research - Relationship Has Not Ended
Any financial relationship that was found to be relevant has been mitigated.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Colorado Medical Society and DaVita, Inc. The Colorado Medical Society is accredited by the ACCME to provide continuing medical education for physicians.
Test Information
75 %
100 %
7/8/2026
Continue to Enduring Material